This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Systemic Juvenile Idiopathic Arthritis전신발병형 연소성 관절염 (전신발병형연소성관절염)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M08.2 | Special Copayment Reduction: V133 (rare disease)
B. SynonymsJuvenile arthritis with systemic onset
C. Adult onsetLikelihood of first onset in adulthood low — systemic-onset juvenile arthritis (sJIA) mainly has onset in infants and young children (1–5 years) but can occur at any age up to 16. The same clinical picture in adults is classified separately as adult-onset Still disease (AOSD).
1. History

Juvenile Rheumatoid Arthritis (JRA) or juvenile idiopathic arthritis (Juvenile Idiopa…

2. Causes

The pathogenesis of Systemic Juvenile Idiopathic Arthritis (sJIA) is explained by an autoinflammatory mechanism…

3. Genetics

The genetic risk factors for systemic-onset JIA are similar to those of adult AOSD. HLA associations are weaker than in other JIA subtypes, and IL-6, IL-18, NLR…

4. General epidemiology

Systemic-onset JIA accounts for about 10–15% of all JIA. The age-of-onset distribution peaks at 1–5 years, and there is no sex difference or boys and girls are similarly…

5. Pathophysiology

The pathophysiology of joint inflammation in juvenile arthritis differs by subtype. Common mechanisms include monocytes, macrophages, T cells and B cells within the synovium…

6. Symptoms

The three main clinical symptoms of systemic-onset JIA are fever, salmon-colored rash and arthritis. Fever: 38.5°C or higher…

7. Signs

On physical examination, joint swelling, warmth, limited range of motion and flexion contractures are the main signs. Longer morning stiffness reflects more severe inflammation. …

8. Screening

Screening for juvenile arthritis is performed in children with joint swelling or morning stiffness persisting for 6 weeks or longer. Basic screening tests include CBC, ESR, CRP,…

9. Diagnosis

The diagnosis of juvenile arthritis is made according to the 2001 revised International League of Associations for Rheumatology (ILAR) classification criteria. Core criteria: onset before age 16, 6 weeks or longer…

10. Treatment

As in AOSD, IL-1β and IL-6 blockade is central to the treatment of systemic-onset JIA. NSAIDs are used as initial treatment for mild symptoms, but alone their effect…

11. Prognosis

The prognosis of systemic-onset JIA differs greatly by course pattern (monophasic, relapsing, persistent chronic arthritis). In about 30%, within months to years, self-limited…

12. Prevention

Primary prevention of juvenile arthritis is impossible, but early diagnosis and treatment and prevention of complications are important. Regular ophthalmologic slit-lamp examination in ANA-positive oligoarticular patients…

13. References10 papers in major international journals.

1. History

Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) is an umbrella concept for chronic arthritis occurring in children younger than 16, with a long history and a complex development of classification. The earliest record is the description of chronic arthritis in children by Charles West of England in 1864, and in 1897 George Frederic Still described in detail chronic arthritis in children accompanied by systemic symptoms (fever, rash, lymphadenopathy), and it became known as 'Still disease'.

In the early-to-mid 20th century, childhood arthritis was regarded as a pediatric form of adult rheumatoid arthritis (RA), but immunologic research in the 1970s–80s confirmed that childhood arthritis is a heterogeneous group of diseases considerably different from RA both clinically and immunologically. In 1977, the American College of Rheumatology (ACR) proposed criteria classifying JRA (Juvenile Rheumatoid Arthritis) into 3 onset types (systemic, polyarticular, oligoarticular). In 1994, a European group separately established JCA (Juvenile Chronic Arthritis) criteria.

Subsequently, in 1997–2001, the International League of Associations for Rheumatology (ILAR) integrated these two classifications and proposed a new classification system called JIA (Juvenile Idiopathic Arthritis). The ILAR JIA classification consists of 7 subtypes (systemic, persistent oligoarticular, extended oligoarticular, RF-negative polyarticular, RF-positive polyarticular, psoriatic arthritis, enthesitis-related arthritis, undifferentiated). With the introduction of biologics (etanercept, abatacept, anakinra, tocilizumab, secukinumab, etc.), treatment of JIA has improved greatly since the 2000s.

2. Causes

The pathogenesis of Systemic Juvenile Idiopathic Arthritis (sJIA) is explained by an autoinflammatory mechanism. As in adult AOSD, excessive secretion of IL-1β and IL-18 due to NLRP3 inflammasome activation is central. Innate immune overactivation caused by infection (especially parvovirus B19, EBV, Mycoplasma pneumoniae) leads to uncontrolled systemic inflammation in genetically susceptible children. IL-6 induces the acute phase response (fever, elevated CRP, leukocytosis), and IL-18 activates NK cells and CD8+ T cells, triggering IFN-γ secretion. Mutual reinforcement of IFN-γ and IL-18 is the pathogenesis of macrophage activation syndrome (MAS). In some patients, a 'phenotypic shift' occurs over the disease course in which the IL-17 pathway becomes prominent, associated with the risk of lung involvement (interstitial lung disease).

3. Genetics

The genetic risk factors for systemic-onset JIA are similar to those of adult AOSD. HLA associations are weaker than in other JIA subtypes, and polymorphisms of autoinflammation-related genes such as IL-6, IL-18, NLRP3 and IRAK3 have been reported. Recent studies report that promoter polymorphisms of the MIF (macrophage migration inhibitory factor) gene and IL-1β-related genes are associated with sJIA risk. The low concordance rate in identical twins suggests the importance of environmental factors. Familial clustering is rare, and the significance of genetic counseling is limited.

4. General epidemiology

Systemic-onset JIA accounts for about 10–15% of all JIA. The age-of-onset distribution peaks at 1–5 years, and there is no sex difference or boys and girls are similarly affected. It occurs in all races worldwide. The most serious complication of sJIA is macrophage activation syndrome (MAS/sHLH), which occurs in about 10–15% of patients with sJIA and carries mortality. Recently, sJIA-associated lung disease (sJIA-LD) has been recognized as an important complication occurring during the use of biologics. In Korea as well, registration and treatment of patients with sJIA are carried out mainly at pediatric rheumatology centers.

5. Pathophysiology

The pathophysiology of joint inflammation in juvenile arthritis differs by subtype. Common mechanisms include infiltration and activation of monocytes, macrophages, T cells and B cells within the synovium, proliferation and angiogenesis of fibroblast-like synoviocytes (FLS) and secretion of cartilage- and bone-destroying enzymes (RANKL, MMP, cathepsin). In the RF-positive polyarticular type, as in adult RA, anti-CCP antibody-mediated immune complexes induce complement activation in the joint, and ACPA (anti-CCP)-specific T cells sustain joint inflammation. In the systemic type, the pathway of NLRP3 inflammasome activation → excessive IL-1β and IL-18 secretion → macrophage activation (MAS risk) is central. In enthesitis-related arthritis, the IL-17/IL-23 axis and HLA-B27-related endoplasmic reticulum stress mechanisms cause enthesis inflammation. In the oligoarticular type, an imbalance of Th17 cells and regulatory T cells results in excessive IL-17 secretion within the joint.

6. Symptoms

The three main clinical symptoms of systemic-onset JIA are fever, salmon-colored rash and arthritis. Fever: an afternoon-to-evening spike pattern of 38.5°C or higher (1–2 times a day) persisting for several weeks or longer. The general condition temporarily improves after defervescence. Salmon-colored rash: pink-to-salmon non-pruritic maculopapules appearing with fever. The rash is transient, appearing with fever and disappearing with defervescence. Light friction or heat applied to the lesion makes the rash more prominent (Koebner phenomenon). Arthritis: in young children, there may initially be only arthralgia without joint swelling. When it progresses to polyarthritis, the knees, ankles, wrists and cervical spine are commonly involved. Lymphadenopathy (cervical, axillary, inguinal), hepatosplenomegaly and serosal effusions (pleuritis, pericarditis) may accompany it. When MAS develops, persistent high fever, pancytopenia, rapid deterioration of liver function and coagulation abnormalities appear and are life-threatening.

7. Signs

On physical examination, joint swelling, warmth, limited range of motion and flexion contractures are the main signs. Longer morning stiffness reflects more severe inflammation. In the systemic type, daily afternoon fever spikes and a salmon-colored rash (appearing with fever and disappearing with defervescence) are characteristic. When uveitis is present, slit-lamp examination confirms findings of anterior uveitis, and because it is initially asymptomatic, regular ophthalmologic examination for screening is needed. Growth impairment (local or generalized), leg length discrepancy and joint deformities may appear in children with long-standing involvement. Laboratory findings used for diagnosis include elevated ESR and CRP, thrombocytosis, anemia (anemia of chronic disease), RF (positive in the positive polyarticular type) and ANA (positive in about 50–60% of the oligoarticular type).

8. Screening

Screening for juvenile arthritis is performed in children with joint swelling or morning stiffness persisting for 6 weeks or longer. Basic screening tests include CBC, ESR, CRP, RF, ANA, liver and kidney function and uric acid. Because ANA-positive oligoarticular patients have a high risk of uveitis, they are referred immediately for pediatric ophthalmologic slit-lamp examination and screened regularly thereafter. HLA-B27 testing is performed when enthesitis-related arthritis or an ankylosing spondylitis variant is suspected. Anti-CCP antibody testing is used in RF-positive patients or patients with adolescent-onset polyarthritis to assess continuity with adult RA. Joint ultrasound is used to assess clinically unclear joint effusion and synovial thickening.

9. Diagnosis

The diagnosis of juvenile arthritis is made according to the 2001 revised International League of Associations for Rheumatology (ILAR) classification criteria. Core criteria: onset before age 16, arthritis of one or more joints persisting for 6 weeks or longer and exclusion of other causes. Subtype classification is based on the clinical features of the first 6 months of onset (number of joints, RF, ANA, HLA-B27, systemic symptoms). The differential diagnosis includes infectious arthritis (septic, viral), reactive arthritis, rheumatic fever, systemic lupus erythematosus (SLE), seronegative spondyloarthropathy and growing pains. Joint radiography (may be negative early), joint MRI (assessment of early synovial thickening and cartilage and bone damage) and joint ultrasound are used to support diagnosis.

10. Treatment

As in AOSD, IL-1β and IL-6 blockade is central to the treatment of systemic-onset JIA. NSAIDs are used as initial treatment for mild symptoms, but alone their effect is limited. Systemic steroids are used for acute severe fever and arthritis, with the goal of minimizing long-term use. Anakinra: IL-1RA, rapid effect in treating acute flares and MAS. Canakinumab: anti-IL-1β, for maintaining long-term remission, approved for sJIA treatment worldwide including Korea. Tocilizumab: anti-IL-6R, effective when IL-1 blockade is insufficient or in the chronic arthritis type. When sJIA-associated lung disease (sJIA-LD) develops, intensified immunosuppression and pulmonology consultation are needed. When MAS develops, an HLH protocol including high-dose steroids + anakinra or cyclosporine is applied.

11. Prognosis

The prognosis of systemic-onset JIA differs greatly by course pattern (monophasic, relapsing, persistent chronic arthritis). About 30% have self-limited remission within months to years, about 30% have repeated relapses and about 40% have persistent chronic arthritis. Since the introduction of biologics (anakinra, canakinumab, tocilizumab), the complete remission rate has improved greatly. MAS remains a major cause of death, and early recognition and aggressive treatment are decisive for improving survival. sJIA-associated lung disease is a complication that has recently drawn attention; it occurs during the use of biologics and is difficult to treat. Growth delay, osteoporosis and steroid-related complications affect long-term morbidity.

12. Prevention

Primary prevention of juvenile arthritis is impossible, but early diagnosis and treatment and prevention of complications are important. In ANA-positive oligoarticular patients, regular ophthalmologic slit-lamp examination (every 4 months to 1 year after onset) detects and treats asymptomatic uveitis early. To prevent joint damage, early complete remission is targeted with a treat-to-target strategy. During immunosuppressive treatment, infections are prevented with vaccination (inactivated vaccines recommended, live vaccines contraindicated). Physical therapy, occupational therapy and sports rehabilitation maintain joint range of motion and muscle strength. Adjustments in school and social environments (education, accommodation in physical activities) are important for supporting the normal development of children.

13. References

  1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392. PMID: 14760812.
  2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. DOI: 10.1016/S0140-6736(07)60363-8. PMID: 17336654.
  3. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(4):465-482. DOI: 10.1002/acr.20459. PMID: 21452260.
  4. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-1209. PMID: 9214419.
  5. Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290-2294. PMID: 15517650.
  6. Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am. 2012;59(2):301-327. DOI: 10.1016/j.pcl.2012.03.014. PMID: 22560573.
  7. Klein A, Minden K, Hospach A, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(7):969-974. DOI: 10.1136/annrheumdis-2019-216579. PMID: 32350026.
  8. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658-666. DOI: 10.1002/art.24516. PMID: 19405003.
  9. Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(2):545-555. DOI: 10.1002/art.30128. PMID: 21280009.
  10. Horneff G, De Buck M, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68(4):519-525. DOI: 10.1136/ard.2007.087593. PMID: 18445619.